Esophageal Cancer
ACG unveils gastric premalignancy guidelines aligned with colon, esophagus surveillance
The ACG has released its first guidance for gastric premalignant conditions, such as atrophic gastritis, gastric intestinal metaplasia and dysplasia, in sync with surveillance recommendations established for the colon and esophagus.
Methylated DNA biomarker panel noninvasively detects esophageal cancer, precursors
A methylation biomarker panel paired with a minimally invasive sponge-capsule device identified Barrett’s esophagus, esophageal adenocarcinoma and high-grade dysplasia, according to a study published in American Journal of Gastroenterology.
Travel to high-volume centers for esophageal cancer surgery linked to longer survival
Patients who traveled to high-volume centers for esophagectomy experienced better outcomes than those who sought treatment locally at low-volume centers, according to results of a cohort study.
Obesity linked to higher risk for Barrett’s esophagus progression to dysplasia, cancer
Among patients with Barrett’s esophagus, every 5 kg/m2 increase in BMI was associated with up to a 6% relative increase in the risk for malignant progression, according to a systematic review and meta-analysis.
Individualized neoantigen therapy could be ‘huge leap’ toward personalized medicine
A novel therapeutic approach stimulated new and existing T-cell responses among patients with melanoma or non-small cell lung cancer, according to results of a phase 1 trial.
Prognostic tool may identify those with BE at higher risk for developing esophageal cancer
The biomarker-based Esopredict determined that patients with Barrett’s esophagus who were stratified as higher risk were 6.4-times more likely to progress to high-grade dysplasia or esophageal adenocarcinoma within 5 years, research showed.
Probability-based screening for BE, esophageal cancer could reduce screening needs by 45%
Targeted screening of older adults with GERD and a 5% probability of Barrett’s esophagus or esophageal adenocarcinoma could “substantially decrease” the population to screen, while still detecting more than 70% of disease, data showed.
Chemotherapy regimen improves survival in advanced esophageal cancer
CHIGAGO — Perioperative chemotherapy improved OS in patients with locally advanced esophageal adenocarcinoma compared with chemoradiation prior to surgery, results form a randomized phase 3 trial presented at ASCO Annual Meeting showed.
Endoscopic, histologic improvements in EoE sustained at 52 weeks with etrasimod
WASHINGTON — Once-daily etrasimod 1 mg and 2 mg was well-tolerated and sustained improvements in histological and endoscopic features of eosinophilic esophagitis, as well as patient symptoms, through 52 weeks of treatment, according to data.
FDA approves Tevimbra for certain adults with advanced esophageal cancer
The FDA approved tislelizumab-jsgr as a monotherapy for the treatment of certain adults with unresectable or metastatic esophageal squamous cell carcinoma, according to a press release.